Nasdaq:US$16.46 (-0.22) | HKEX:HK$26.55 (-0.10) | AIM:£2.67 (-0.01)
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2015-05-01

ASCO 2015: Preliminary results of TATTON, a multi-arm Phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 (savolitinib) or selumetinib in EGFR-mutant lung cancer

Please see

The associated abstract is available at

Meeting: 2015 ASCO Annual Meeting
Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Sub-category: Signal Transduction
Abstract No: 2509
Poster Board Number: Board #225
Citation: J Clin Oncol 33, 2015 (suppl; abstr 2509)
Author(s): Oxnard G.R., et al.
Date & Time: Saturday 30 May 8:00 AM–11:30 AM